Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Axovant Sciences Ltd (NQ: AXON)
2.110 USD  -0.050 (-2.31%)
Official Closing Price  /  Updated: 5:20 PM EDT, Oct 22, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 553,851
Open 2.160
Bid (Size) 2.050 (30)
Ask (Size) 2.230 (50)
Prev. Close 2.160
Today's Range 2.050 - 2.240
52wk Range 1.020 - 6.590
Shares Outstanding 107,788,074
Dividend Yield N/A
Performance
YTD
-60.26%
-60.26%
1 Month
-7.46%
-7.46%
3 Month
-13.52%
-13.52%
6 Month
+100.95%
+100.95%
1 Year
-61.71%
-61.71%
Top News
More News
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teva Pharmaceutical... Read More
from GlobeNewswire News Releases
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases, today announced upcoming presentations regarding its... Read More
from GlobeNewswire News Releases
More News
Read More
Axovant to Present at Two Upcoming Investor Conferences
from GlobeNewswire News Releases
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
from PR Newswire
Axovant to Present at Upcoming Investor Conferences
from GlobeNewswire News Releases
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
from GlobeNewswire News Releases
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
from GlobeNewswire News Releases
How The Parts Add Up: IBB Targets $141
category ETFs
from ETF Channel
3 Biotech Stocks That Soared This Week: Are They Buys?
category AXON , BNTC , Market News , and 2 more.
from Motley Fool
3 Gene Therapy Stocks Investors Can Bet On In Rest Of 2018
category Pharma/Biotech , Stocks / Equities
from Blogs - TalkMarkets
The Sad Truth: This Biotech Investing Strategy Almost Always Works
category Market News , LLY , AXON , and 2 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.